Diagnostik og behandling af maturity onset diabetes of the young type 3
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Maturity onset diabetes of the young type 3 (MODY3) is the most prevalent type of monogenetic diabetes. Treatment guidelines differ from both Type 1 diabetes and Type 2 diabetes. First-line treatment is a long-acting sulphonylurea, which lowers the plasma glucose level effectively, however with the risk of hypoglycaemia. When hypoglycaemia is a problem, short-acting sulphonylureas, glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors may be used as alternatives. Metformin, glitazones and sodium glucose transporter 2-inhibitors have only limited applicability in MODY3. Further research needs to evaluate combinational therapy.
Bidragets oversatte titel | Diagnosis and treatment of maturity onset diabetes of the young type 3 |
---|---|
Originalsprog | Dansk |
Artikelnummer | V06170502 |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 180 |
Antal sider | 6 |
ISSN | 0041-5782 |
Status | Udgivet - 2018 |
- Diabetes Mellitus, Type 2/diagnosis, Humans, Hypoglycemic Agents/therapeutic use, Insulin-Secreting Cells/metabolism, Sulfonylurea Compounds/therapeutic use
Forskningsområder
Links
- http://ugeskriftet.dk/videnskab/diagnostik-og-behandling-af-maturity-onset-diabetes-young-type-3
Forlagets udgivne version
ID: 215864269